Neuromyelitis Optica Program
What we do
The Neuromyelitis Optica Program at ½û·¬¶¯Âþ is recognized as a world leader in the research and treatment of NMOSD including both aquaporin-4 antibody-positive patients and patients who are seronegative or have MOGAD. While all faculty members treat and manage patients with NMOSD, we collaborate with the , , and to offer comprehensive care to patients with NMOSD for individuals worldwide.